A Phase III Study of Abatacept in Japanese Subjects With Rheumatoid Arthritis

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Abatacept

Registration Number: NCT00484289

Lead Sponsor: Bristol-Myers Squibb

Brief Summary: The purpose of this study is to demonstrate the safety of chronic use of abatacept in Japanese Subjects with Rheumatoid Arthritis (RA) having completed clinical studies IM101-071, IM101-034, and also Disease Modifying Anti-Rheumatic Drugs (DMARDs) failures with MTX intolerance.

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 217

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Arm 2: Participants from Phase II study (IM101-071)	Abatacept	-
Arm 3: New Participants with Methotrexate (MTX) Intolerance	Abatacept	-
Arm 1: Participants from Phase I study (IM101-034)	Abatacept	-

Primary Outcome Measures

Name	Time	Method
Number of Participants With Vital Signs, Physical Examinations, and Electrocardiogram Findings That Were Considered to be AEs by the Investigator	At week 0, 2, 4; then once every 4 weeks up to 48 months; then once in every 3 months or 12 weeks to end of study (27 Dec 2010). The overall mean duration of exposure to the study drug was approximately 3 years (34.3 ± 10.7 months).
Number of Participants With Abnormal Laboratory Changes (ALC)	From initiation of the study drug (31 Mar 2008) to data cutoff (27 Dec 2010). The overall mean duration of exposure to the study drug was approximately 3 years (34.3 ± 10.7 months).	The laboratory tests were analyses included enzyme, gastrointestinal, hematology, hepatobiliary, lipid, metabolic, nutritional, blood gas, microbiology, serology, protein, chemistry, renal, urinary tract, urinalyses, water, electrolyte and mineral investigations.
Number of Participants With Adverse Events (AE), Serious Adverse Events (SAE), and Discontinuations Due to AEs	From initiation of the study drug (31 Mar 2008) to data cutoff (27 Dec 2010). The overall mean duration of exposure to the study drug was approximately 3 years (34.3 ± 10.7 months).	AE is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition. SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a cancer, is a congenital anomaly/birth defect, results in the development of drug dependency or drug abuse, is an important medical event. Both subjective and objective AEs and SAEs are included.

Secondary Outcome Measures

Name	Time	Method
Percentage of Participants With ACR 70 Response Over Time	At weeks 4, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192.	ACR 70 response requires a participant to have a 70% reduction in the number of swollen and tender joints, and a reduction of 70% in three of the following five parameters: physician global assessment of disease activity, participant global assessment of disease activity, participant global assessment of pain, C-reactive protein, and degree of disability in Health Assessment Questionnaire score.
Baseline (BL) and Postbaseline (PBL) Disease Activity Scores (DAS 28)	At BL (week 0), week 24, 48, 96, 144, and 192.	The DAS 28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, CRP levels, and participant assessment of disease activity measure on a visual analogue scale of 100 mm. The DAS28 has numeric thresholds that define high disease activity (change of \> 5.1), low disease activity (change of ≤ 3.2) and remission (\< 2.6). Please see outcome 8 for change from BL data.
Change From Baseline in DAS 28 Scores at Week 24, 48, 96, 144, and 192	At BL (week 0), weeks 24, 48, 96, 144, and 192.	The DAS 28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, CRP levels, and participant assessment of disease activity measure on a visual analogue scale of 100 mm. The DAS28 has numeric thresholds that define high disease activity (\> 5.1), low disease activity (≤ 3.2) and remission (\< 2.6). Please refer to outcome 7 for BL and PBL values.
Change From Baseline in Mental Component Summary (MCS) of Health-Related Quality of Life (SF-36) Score at Weeks 24, 48, 96, 144, and 192	At BL (Week 0), weeks 24, 48, 96, 144, and 192.	The SF-36 covers 8 health dimensions including 4 physical (physical function, role functioning \[physical\], bodily pain, and general health) and 4 mental subscales (vitality, social function, role emotional, and mental health). All subscales were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from a minimum of 0 to a maximum of 100, higher score indicating better quality of life. Improvements of \> 3 points were considered clinically meaningful.Please see outcome 15 for BL and PBL values.
Percentage of Participants With American College of Rheumatology (ACR 20) Response Over Time	At weeks 4, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192.	ACR 20 response requires a participant to have a 20% reduction in the number of swollen and tender joints, and a reduction of 20% in three of the following five parameters: physician global assessment of disease activity, participant global assessment of disease activity, participant global assessment of pain, C-reactive protein, and degree of disability in Health Assessment Questionnaire score.
Number of Participants With Low Disease Activity Score (DAS 28 Score ≤ 3.2) at Weeks 24, 48, 96, 144, 192	At weeks 24, 48, 96, 144, and 192.	The DAS28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, CRP levels, and participant assessment of disease activity measure on a visual analogue scale. Participants with DAS 28 score ≤ 3.2 were considered to have low disease activity.
Baseline and Postbaseline Physical Component Summary (PCS) of Health-Related Quality of Life (SF-36) Scores	At BL (week 0), weeks 24, 48, 96, 144, and 192.	The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role functioning \[physical\], bodily pain, and general health) and 4 mental subscales (vitality, social function, role emotional, and mental health). All subscales were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from 0 to 100, with a higher score indicating better quality of life. Improvements of \> 3 points were considered clinically meaningful.Please see outcome 14 for change from BL data.
Baseline and Postbaseline Mental Component Summary (MCS) of Health-Related Quality of Life (SF-36) Scores	At BL (week 0), weeks 24, 48, 96, 144, and 192.	The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role functioning \[physical\], bodily pain, and general health) and 4 mental subscales (vitality, social function, role emotional, and mental health). All subscales were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from 0 to 100, with a higher score indicating better quality of life. Improvements of \> 3 points were considered clinically meaningful. Please see outcome 14 for change from BL data.
Percentage Decrease in C-reactive Protein Levels From Baseline at Weeks 24, 48, 96, 144, and 192	At BL (week 0), weeks 24, 48, 96, 144, and 192.	CRP is an acute phase reactant protein that is a clinical marker for Rheumatoid Arthritis (RA) and is a core component of the ACR scoring system. CRP was evaluated from serum samples. Increasing levels indicate increasing level of disease, negative values indicate improvement. Percentage improvement from BL = (BL - PBL value) / BL value \* 100. Please refer to outcome 17 for BL and PBL values.
Number of Participants With DAS 28 Score Change ≥ 1.2 From Baseline at Weeks 24, 48, 96, 144, and 192	At BL (week 0), weeks 24, 48, 96, 144, and 192.	The DAS 28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, CRP levels, and participant assessment of disease activity measure on a visual analogue scale. Participants with DAS 28 score change ≥ 1.2 from BL were considered to have improvement.
Percentage of Participants Who Achieved a Reduction of At Least 0.3 Units From Baseline in Health Assessment Questionnaire (HAQ) at Weeks 24, 48, 96, 144, 192	At BL (week 0), weeks 24, 48, 96, 144, and 192.	The disability section of the full HAQ includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities. The questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3= unable to do. Higher scores= greater dysfunction. A disability index was calculated by summing the worst scores in each domain and dividing by the number of domains answered. Clinically meaningful HAQ response=an improvement of at least 0.3 units from BL in HAQ.
Change From Baseline in Physical Component Summary (PCS) of Health-Related Quality of Life (SF-36) Score at Weeks 24, 48, 96, 144, and 192	At baseline (week 0), weeks 24, 48, 96, 144, and 192.	The SF-36 covers 8 health dimensions including 4 physical (physical function, role functioning \[physical\], bodily pain, and general health) and 4 mental subscales (vitality, social function, role emotional, and mental health). All subscales were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from a minimum of 0 to a maximum of 100, higher score indicating better quality of life. Improvements of \>3 points were considered clinically meaningful. Please see outcome 13 for BL and PBL values.
Baseline and Postbaseline C-reactive Protein (CRP) Levels	At BL (week 0), weeks 24, 48, 96, 144, and 192.	CRP is an acute phase reactant protein that is a clinical marker for Rheumatoid Arthritis (RA) and is a core component of the ACR scoring system. CRP was evaluated from serum samples. Increasing levels indicate increasing level of disease. Please see outcome 18 for change from BL data.
Percentage of Participants With ACR 50 Response Over Time	At weeks 4, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192.	ACR 50 response requires a participant to have a 50% reduction in the number of swollen and tender joints, and a reduction of 50% in three of the following five parameters: physician global assessment of disease activity, participant global assessment of disease activity, participant global assessment of pain, C-reactive protein, and degree of disability in Health Assessment Questionnaire score.
Number of Participants Who Were Positive for Anti-abatacept and Anti-CTLA4-T Antibodies	At BL (week 0), weeks 24, 48, 72, 96, 120, 144, 168, and 192.	Validated enzyme-linked immunoassay (ELISA) method was used to measure anti-abatacept and anti-CTLA4-T antibody levels. For anti-abatacept antibody ELISA, a sample was considered seropositive if it had a titer of 400 or greater and if immunodepletion was observed. The responses that were negative in initial screen were reported as seronegative with a value of \< 400. A sample was considered positive in CTLA4-T antibody ELISA if it had a titer of 25 or greater and if immunodepletion was observed.
Abatacept PK Parameter: Maximum Serum Concentration at Steady State	Samples were collected predose at week 8, 12, 16, 24; end of infusion at week 12; and at week 13-15 visits.	Maximum plasma concentration is the maximum observed serum drug concentration at steady state (Css max).
Number of Participants in Remission (DAS 28 Score < 2.6) at Weeks 24, 48, 96, 144, 192	At weeks 24, 48, 96, 144, and 192.	The DAS 28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, CRP levels, and participant assessment of disease activity measure on a visual analogue scale. Participants with DAS 28 score \< 2.6 were considered to be in remission.
Baseline and Postbaseline Rheumatoid Factor Levels	At BL (week 0), weeks 24, 48, 96, 144, and 192.	Rheumatoid factor (RF or RhF) is an autoantibody (antibody directed against an organism's own tissues) most relevant in rheumatoid arthritis. It is an antibody against the Fc portion of Immunoglobulin (Ig)G, which is itself an antibody. RF and IgG join to form immune complexes which contribute to the disease process. RF levels are considered positive if value is \>20 and considered negative if value is \<20. Please see outcome 20 for change from BL data.
Abatacept PK Parameter: Total Body Clearance	Samples were collected predose at week 8, 12, 16, 24; end of infusion at week 12; and at week 13-15 visits.	Total body clearance is the rate and extent at which the drug is eliminated from the body. The clearance of a drug is used to understand the processes involved in drug elimination, distribution and metabolism.
Change From Baseline in Rheumatoid Factor Levels at Weeks 24, 48, 96, 144, and 192	At BL (week 0), weeks 24, 48, 96, 144, and 192.	RF is an autoantibody (antibody directed against an organism's own tissues) most relevant in rheumatoid arthritis. It is an antibody against the Fc portion of Immunoglobulin (Ig)G, which is itself an antibody. RF and IgG join to form immune complexes which contribute to the disease process. RF levels are considered positive if value is \>20 and considered negative if value is \<20. Please refer to outcome 19 for BL and PBL values.
Abatacept PK Parameter: Area Under the Serum Concentration-time Curve at Steady State	Samples were collected predose at week 8, 12, 16, 24; end of infusion at week 12; and at week 13-15 visits.	Area under the plasma concentration-time curve (AUCss) at steady state for each dosing interval was determined using the linear trapezoidal rule.
Abatacept PK Parameter: Minimum Plasma Concentration at Steady State	Samples were collected predose at week 8, 12, 16, 24; end of infusion at week 12; and at week 13-15 visits.	Minimum Plasma Concentration (Cmin) is the minimum observed serum drug concentration at steady state.